New cocktail of drugs tested for Hard-to-Treat breast cancer – but trial halted early
Disease control
Terminated
This phase II study tested several drug combinations for people with metastatic triple-negative breast cancer, a type that has spread and lacks common hormone targets. The drugs included olaparib (a PARP inhibitor) paired with either durvalumab (an immunotherapy), selumetinib, ca…
Phase: PHASE2 • Sponsor: Gordon Mills, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC